Homepage Top Section1

SLN124 is being developed for the treatment of iron overload disorders like ß -Thalassemia, Myelodysplastic syndrome (MDS) and Hereditary Hemochromatosis (HH). The investigational candidate was demonstrated to reduce

The companies have reached settlement more than five years after the litigation started with Xarelto. During the period, all six cases related to Xarelto went to trial. Bayer

The further positive data from the DREAMM-1 study, which is based on results of the pre-specified interim analysis, showed the durability and depth of response of GSK2857916 anti-BCMA

The findings of the study, called European Sudden Cardiac Arrest network (ESCAPE-NET), were presented at European Heart Rhythm Association (EHRA) 2019. It evaluated if nifedipine and amlodipine –

Under The collaboration agreement will enable Merck to use Iktos generative modelling AI technology to facilitate the rapid and cost-effective discovery and design of new compounds. The agreement

The research team used a single low dose of Novartis’ leukemia drug Tasigna (nilotinib) in a phase II clinical trial in Parkinson’s disease patients. The researchers claimed that

According to Seres Therapeutics, the partners will research to assess microbiome-based approaches as a predictor for which cancer immunotherapies get the best response from patients. In addition, the

Oncternal Therapeutics will be the name of the combined company, which will engage in the development of potential first-in-class therapeutic candidates for cancers. As per terms of the

The 30-week long trial, dubbed Sustain 9, assessed the efficacy and safety of Ozempic injection 1.0 mg in combination with the SGLT-2 inhibitors against placebo. The drug was